Home/Filings/4/0001209191-19-037525
4//SEC Filing

Cheruvu Pavan 4

Accession 0001209191-19-037525

CIK 0001636050other

Filed

Jun 16, 8:00 PM ET

Accepted

Jun 17, 7:09 PM ET

Size

5.4 KB

Accession

0001209191-19-037525

Insider Transaction Report

Form 4
Period: 2019-06-14
Cheruvu Pavan
Chief Executive Officer
Transactions
  • Purchase

    Common Stock

    2019-06-14$5.21/sh+7,500$39,0757,500 total
Footnotes (1)
  • [F1]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9798 to $5.35 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Issuer

Axovant Gene Therapies Ltd.

CIK 0001636050

Entity typeother

Related Parties

1
  • filerCIK 0001731741

Filing Metadata

Form type
4
Filed
Jun 16, 8:00 PM ET
Accepted
Jun 17, 7:09 PM ET
Size
5.4 KB